Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 92

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 92
---
 certain proposed changes;                                           |

| • |     | Dr. Lennon contacted the Bidder B CEO via telephone to ask for an extension of the deadline for Aadi to                                                    
 respond to the Bidder B December 17 Proposal given the short period of time to respond, but was informed that there would be no extension of the deadline; |

| • |     | Representatives of Bidder B communicated to representatives of Leerink Partners that no proposed changes to the 
 exclusivity agreement were acceptable;                                                                          |

| • |     | Representatives of Nomura communicated to representatives of Leerink Partners that Kaken Parent was willing to                                                                                
 improve its offer to $95 million and drop the requirement for an escrow fund if Aadi agreed to enter into exclusivity with Kaken Parent through 12:00 a.m. Eastern time on December 21, 2024; |

| • |     | At the direction of Aadi’s board of directors, representatives of Leerink Partners communicated to                                                                                   
 representatives of Bidder B that Aadi would not be able to accept the Bidder B December 17 Proposal before the 12:59 a.m. Eastern time deadline the following day (December 18); and |

| • |     | At the direction of Aadi’s board of directors, representatives of Leerink Partners informed representatives                                                        
 of Nomura that Aadi was willing to agree to exclusivity with Kaken Parent if Kaken Parent agreed to improve the amount of the base purchase price to $100 million. |

On December 18, 2024, representatives of Nomura delivered to representatives of Leerink Partners an updated non-bindingindication of interest pursuant to which Kaken Parent would (i) acquire the FYARRO business by purchasing Aadi Sub for a base purchase price of $100 million (payable from Kaken Parent’s balance sheet), on a debt-free and cash-free basis, and (ii) withdraw its proposal to include an escrow account in the Divestiture Agreement (the “Kaken December 18 Proposal”). The indication of interest also stated that it was Kaken Parent’s final offer and was predicated on Aadi entering into exclusivity with Kaken Parent through 12:00 a.m. Eastern time on December 21, 2024. On that same day, representatives of Leerink Partners delivered to representatives of Nomura a letter signed by Dr. Lennon stating that, based on the Kaken December 18 Proposal, Aadi would agree to enter into exclusivity through 12:00